1. Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015;100(8):2849–52.
2. Sodium-glucose cotransporter-2 (SGLT2) inhibitors. US Food and Drug Administration. 2018.
https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/sodium-glucose-cotransporter-2-sglt2-inhibitors
. Accessed 02/25/2020.
3. Ogawa W, Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. J Diabetes Investig. 2016;7(2):135–8.
4. FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. U.S. Food and Drug Administration. 2015.
https://www.fda.gov/files/drugs/published/Drug-Safety-Communication%2D%2DFDA-warns-that-SGLT2-inhibitors-for-diabetes-may-result-in-a-serious-condition-of-too-much-acid-in-the-blood.pdf
. Accessed 02/25/2020.
5. Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015;38(9):1680–6.